These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 2676044)

  • 21. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
    Cogle CR; Moreb JS; Leather HL; Finiewicz KJ; Khan SA; Reddy VS; Wingard JR
    Am J Hematol; 2003 Jul; 73(3):169-75. PubMed ID: 12827653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
    Lu C; Braine HG; Kaizer H; Saral R; Tutschka PJ; Santos GW
    Cancer Treat Rep; 1984 May; 68(5):711-7. PubMed ID: 6373004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
    Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
    Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
    Ratanatharathorn V; Karanes C; Lum LG; Uberti J; Dan ME; de Planque MM; Schultz KR; Cronin S; Leisz MC; Mohamed A
    Bone Marrow Transplant; 1992 Jan; 9(1):49-55. PubMed ID: 1543949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
    Ritchie DS; Szer J; Roberts AW; Shuttleworth P; Grigg AP
    Bone Marrow Transplant; 2002 Nov; 30(10):645-50. PubMed ID: 12420202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
    Petersen FB; Buckner CD; Appelbaum FR; Sanders JE; Bensinger WI; Storb R; Deeg HJ; Witherspoon RP; Sullivan KM; Clift RA
    Bone Marrow Transplant; 1992 Jul; 10(1):83-8. PubMed ID: 1515884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
    Jillella AP; Doria R; Khan K; Zelterman D; Ahmad YH; Smith BR; Holmes W; Becker P; Roberts KB; Rappeport JM
    Bone Marrow Transplant; 1999 Jun; 23(11):1095-100. PubMed ID: 10382947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Inoue T; Ikeda H; Yamazaki H; Tang JT; Song C; Teshima T; Murayama S; Ohtani M; Shibata H; Masaoka T
    Strahlenther Onkol; 1993 Apr; 169(4):250-5. PubMed ID: 8488461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Busulfan-containing pre-transplant regimens for the treatment of solid tumors.
    Ghalie R; Reynolds J; Valentino LA; Manson S; Korenblit AD; Feingold JM; Adler SS; Pruett J; Kaizer H
    Bone Marrow Transplant; 1994 Sep; 14(3):437-42. PubMed ID: 7994269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
    Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
    Wachowiak J; Bettoni C; Lange A; Malicki J; Kaczmarek-Kanold M; Głuszak B; Suchnicki K; Daszkiewicz P; Ebell W
    Acta Haematol Pol; 1995; 26(4):377-84. PubMed ID: 8571739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
    Emminger W; Emminger-Schmidmeier W; Haas OA; Urban C; Ambros P; Peters C; Mann G; Fink FM; Ferstl G; Höcker P
    Bone Marrow Transplant; 1992 May; 9(5):313-8. PubMed ID: 1617314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma.
    Copelan EA; Penza SL; Pohlman B; Avalos BR; Goormastic M; Andresen SW; Kalaycio M; Bechtel TP; Scholl MD; Elder PJ; Ezzone SA; O'Donnell LC; Tighe MB; Risley GL; Young DC; Bolwell BJ
    Bone Marrow Transplant; 2000 Jun; 25(12):1243-8. PubMed ID: 10871728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Andersson B; Khouri I; Giralt S; Rios MB; Champlin R; Hester J; Deisseroth AB
    Bone Marrow Transplant; 1994 Jul; 14(1):57-61. PubMed ID: 7951120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is veno-occlusive disease incidence influenced by the total-body irradiation technique?
    Belkacémi Y; Ozsahin M; Rio B; Laporte JP; Leblond V; Pène F; Laugier A
    Strahlenther Onkol; 1995 Dec; 171(12):694-7. PubMed ID: 8545791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome.
    Rubin CM; Mick R; Johnson FL
    Bone Marrow Transplant; 1996 Sep; 18(3):533-40. PubMed ID: 8879614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
    Przepiorka D; Ippoliti C; Giralt S; van Beisen K; Mehra R; Deisseroth AB; Andersson B; Luna M; Cork A; Lee M
    Bone Marrow Transplant; 1994 Sep; 14(3):449-53. PubMed ID: 7994271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.